X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40) 40
humans (37) 37
oncology (32) 32
melanoma (26) 26
female (24) 24
male (20) 20
middle aged (17) 17
adult (15) 15
article (15) 15
immunotherapy (14) 14
ipilimumab (13) 13
metastatic melanoma (13) 13
aged (12) 12
cancer (12) 12
survival (12) 12
care and treatment (10) 10
melanoma - drug therapy (10) 10
nivolumab (10) 10
open-label (10) 10
aged, 80 and over (9) 9
pembrolizumab (9) 9
expression (8) 8
health aspects (8) 8
metastasis (8) 8
mutation (8) 8
research (8) 8
retrospective studies (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
chemotherapy (7) 7
immunology (7) 7
pharmacology & pharmacy (7) 7
prognosis (7) 7
tumors (7) 7
analysis (6) 6
braf (6) 6
double-blind (6) 6
medicine & public health (6) 6
melanoma - genetics (6) 6
melanoma - pathology (6) 6
obstetrics & gynecology (6) 6
pregnancy (6) 6
programmed cell death 1 receptor - antagonists & inhibitors (6) 6
treatment outcome (6) 6
anti-pd-1 (5) 5
antibodies, monoclonal - therapeutic use (5) 5
ctla-4 blockade (5) 5
drug therapy (5) 5
medicine (5) 5
mek (5) 5
melanoma - immunology (5) 5
mortality (5) 5
multicenter (5) 5
neoplasm staging (5) 5
resistance (5) 5
risk factors (5) 5
skin neoplasms - drug therapy (5) 5
survival rate (5) 5
trial (5) 5
turkey (5) 5
untreated melanoma (5) 5
young adult (5) 5
antibodies, monoclonal - administration & dosage (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
apoptosis (4) 4
cell biology (4) 4
children (4) 4
clinical trials (4) 4
cytotoxicity (4) 4
dabrafenib (4) 4
dermatology (4) 4
disease progression (4) 4
disease-free survival (4) 4
drug resistance, neoplasm (4) 4
endocrinology (4) 4
follow-up studies (4) 4
improved survival (4) 4
kaplan-meier estimate (4) 4
melanoma - mortality (4) 4
mutant melanoma (4) 4
mutations (4) 4
original (4) 4
oxidative stress (4) 4
patient outcomes (4) 4
patients (4) 4
pd-1 blockade (4) 4
proto-oncogene proteins b-raf - genetics (4) 4
safety (4) 4
surgery (4) 4
therapy (4) 4
usage (4) 4
uveal melanoma (4) 4
vemurafenib (4) 4
women (4) 4
activation (3) 3
adolescent (3) 3
adverse events (3) 3
age (3) 3
animals (3) 3
antibodies (3) 3
antibodies, monoclonal - adverse effects (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Occupational and Environmental Medicine, ISSN 1076-2752, 09/2018, Volume 60, Issue 9, pp. 860 - 866
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 06/2019, Volume 34, Issue Supplement_1
Journal Article
Nature, ISSN 0028-0836, 04/2016, Volume 532, Issue 7598, pp. 250 - 254
Journal Article
Nature, ISSN 0028-0836, 01/2018, Volume 553, Issue 7688, pp. 347 - 350
Journal Article
Food Quality and Preference, ISSN 0950-3293, 09/2016, Volume 52, pp. 81 - 86
The purpose of this study was to test the validity and reliability of the food choice questionnaire (FCQ) for Turkish consumers. A total of 963 voluntary... 
Validation | Turkish consumers | Food choice questionnaire | EUROPEAN COUNTRIES | FOOD SCIENCE & TECHNOLOGY | VALUES | MOTIVES | CONSUMERS | AGE | MOTIVATIONS | Surveys | Analysis | College teachers
Journal Article
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, ISSN 2212-4403, 2015, Volume 119, Issue 3, pp. e137 - e137
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2013, Volume 72, Issue 1, pp. 263 - 267
Cisplatin-based chemotherapy is recommended for use as first-line treatment for patients with advanced transitional cell carcinoma of the bladder.... 
GEMOX | Renal insufficiency | Oxaliplatin | Medicine & Public Health | Oncology | Cancer Research | Bladder Cancer | Phase II | Pharmacology/Toxicology | METASTATIC UROTHELIAL CANCER | CARBOPLATIN | MULTICENTER | METHOTREXATE | VINBLASTINE | UNFIT | COMBINATION | TUMORS | CISPLATIN-BASED CHEMOTHERAPY | TRIAL | ONCOLOGY | Renal | insufficiency | PHARMACOLOGY & PHARMACY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Renal Insufficiency - physiopathology | Urinary Bladder Neoplasms - physiopathology | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Deoxycytidine - adverse effects | Female | Renal Insufficiency - complications | Kidney - physiopathology | Severity of Illness Index | Glomerular Filtration Rate | Kidney - drug effects | Deoxycytidine - administration & dosage | Carcinoma, Transitional Cell - physiopathology | Thrombocytopenia - physiopathology | Thrombocytopenia - chemically induced | Urinary Bladder Neoplasms - drug therapy | Carcinoma, Transitional Cell - complications | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Urinary Bladder Neoplasms - complications | Drug Monitoring | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Adenocarcinoma | Chemotherapy | Cisplatin | Cancer | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4814 - 4814
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 01/2018, Volume 17, Issue 1, pp. 73 - 83
Targeted therapy options are currently lacking for the heterogeneous population of patients whose melanomas lack BRAF or NRAS mutations (similar to 35% of... 
SIGNALING PATHWAYS | MEK | ACTIVATION | ONCOLOGY | MUTANT MELANOMA | RAF | RESISTANCE | BRAF | KINASE INHIBITOR | MUTATIONS | CANCER | Drugs | Cell culture | Biotechnology | Effectiveness | Target recognition | Toxicity | Xenotransplantation | Melanoma | Cytotoxicity | MAP kinase | Mass spectroscopy | Signaling | Inhibitors | Proteomics | Cell lines | Xenografts | Biocompatibility | Inhibition | Mutation | Mass spectrometry | Tumors | Cancer | melanoma | combination therapy | NRAS | chemical biology | ceritinib
Journal Article
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2018, Volume 11, pp. 9081 - 9089
Major advances in the understanding of the pathophysiology of melanoma have led to a new era of melanoma treatment with targeted therapy and immunotherapies.... 
DABRAFENIB | SURVIVAL | MULTICENTER | LGX818 | advanced melanoma | RAF KINASE | BRAF | OPEN-LABEL | PHASE-3 | MEK162 | MEK | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | DOUBLE-BLIND | binimetinib | INHIBITORS | MAPK PATHWAY | encorafenib | VEMURAFENIB | Antimitotic agents | Care and treatment | Immunotherapy | Melanoma | Metastasis | Antineoplastic agents | Cancer | Urine | Signal transduction | Response rates | Oncology | Internet | Mutation | Kinases | Skin cancer
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2016, Volume 117, pp. S35 - S35
  Objective Vitamin D deficiency is associated with coronary artery disease (CAD) and cardiac mortality. 
Cardiovascular | Calcifediol | Alfacalcidol | Vitamin D | Coronary heart disease | Cardiovascular disease | Vitamin deficiency | Mortality | Coronary vessels
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 4/2016, Volume 17, Issue 2, pp. 99 - 105
Recent data have demonstrated improved survival with targeted and immune therapies in patients with advanced melanoma, leading to much excitement amongst the... 
Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | UNTREATED MELANOMA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MEK INHIBITION | MUTANT MELANOMA | IMPROVED SURVIVAL | RANDOMIZED CONTROLLED-TRIAL | ANTITUMOR IMMUNITY | HUMAN CANCER | DERMATOLOGY | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Combined Modality Therapy - standards | Melanoma - genetics | Immunotherapy | Molecular Targeted Therapy - methods | MAP Kinase Kinase 1 - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Skin Neoplasms - therapy | Standard of Care | CTLA-4 Antigen - immunology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Skin Neoplasms - genetics | Combined Modality Therapy - methods | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Melanoma - therapy | Molecular Targeted Therapy - standards | Usage | Drug therapy, Combination | Drug therapy | Melanoma
Journal Article
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 11/2016, Volume 38, Issue 8, pp. e307 - e309
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 04/2019, Volume 131, pp. 153 - 158
The main objective of this study was to evaluate the pharmacokinetics of ritonavir (RTV) nanosuspension in rats in both fed and fasted state in comparison with... 
Microfluidization | Fasted/fed bioavailability | Point to point relation in IVIVC | Nanosuspension | Ritonavir | DRUG | STABILIZERS | ART | NANOCRYSTALS | RELEASE | SOLUBILITY | HYDROCHLORIDE | DISSOLUTION | ENHANCEMENT | PHARMACOLOGY & PHARMACY | Drugs | Antiviral agents | Drug delivery systems | Powders | Analysis | Pharmacy | Drugstores | Vehicles
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e64338
Journal Article